Rizatriptan (Zyramig)
Rizatriptan
Macleods Pharmaceuticals SA (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Macleods Pharmaceuticals SA (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Zyramig 5mg EACH TABLET CONTAINS: RIZATRIPTAN BENZOATE EQUIVALENT TO RIZATRIPTAN 5,0 mg | 5mg | 47034247/7.3/0342 | Cancelled | Not determined | None |
| Zyramig 10mg EACH TABLET CONTAINS: RIZATRIPTAN BENZOATE EQUIVALENT TO RIZATRIPTAN 10,0 mg | 10mg | 47034347/7.3/0343 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Rizatriptan
- except when in oral solid dosage forms providing 5 mg or less and presented as packs of no more than 2 oral solid dosage forms, indicated for the acute relief of migraine attacks, with or without aura, in patients previously diagnosed by a medical practitioner and initiated on treatment with rizatriptan (S2)
Consolidated Schedules 06 July 2026, lines 7826 to 7828
S2: Rizatriptan
- when in oral solid dosage forms providing 5 mg or less and presented as packs of no more than 2 oral solid dosage forms, indicated for the acute relief of migraine attacks, with or without aura, in patients previously diagnosed by a medical practitioner and initiated on treatment with rizatriptan (S4)
Consolidated Schedules 06 July 2026, lines 2642 to 2644
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Drag to rotate. Structure from PubChem CID 5078.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.